Introduction
Elongation factor 2 kinase (eEF-2K) belongs to a subfamily of atypical protein kinases termed the alpha kinases, of which there are six known in humans.
[1] eEF-2K plays a key role in maintaining cellular homeostasis by impeding the rate of protein synthesis and has been implicated in enhancing tumor cell survival and proliferation. Transient inhibition of protein synthesis has been reported to induce the expression of protooncogenes, stimulating resting cells to enter the cell cycle. [2] Interestingly, breast cancer mitogens upregulate the activity of eEF-2K in human breast cancer; it has been suggested that this promotes cell proliferation. [3] Recently, Leprivier et al. showed that eEF-2K protects cells from nutrient deprivation and facilitates tumor cell adaptation to metabolic stress. [4] In addition, several other reports have suggested eEF-2K as a therapeutic target for treating cancer [5] and depression. [6] Alpha kinases, which are Ser/Thr-specific kinases, bear little sequence similarity to conventional protein kinases; however, their catalytic domains exhibit similarities in structure, exemplified in particular by a common catalytic mechanism. [1, 7] Despite eEF-2K being identified as a therapeutic target, no effective approach to alter its activity in vivo has been reported to date.
Whereas A-484954 shows moderate potency in cells, [8] other attempts to inhibit eEF-2K activity have been largely unsuccessful.
[9] A previous report that NH125 inhibits eEF-2K with high specificity and potency is not supported by recent data. [8, 10] We recently screened recombinant eEF-2K against several collections of small molecules and identified 2,6-diamino-4-(2-fluorophenyl)-4H-thiopyran-3,5-dicarbonitrile (DFTD) as a timedependent inhibitor of eEF-2K. Here we provide kinetic and modeling evidence to support a mechanism of reversible covalent targeting of Cys146 (a nonconserved cysteine residue located at the active site of eEF-2K) by one of the nitrile moieties in the compound. Furthermore, we confirm the reversible covalent inhibition mechanism with the aid of 4-(3-methoxyphenyl)-2,6-dioxopiperidine-3,5-dicarbonitrile (MDP), a related compound containing a similarly appended nitrile group. This work provides the basis for the structure-based design of more potent covalent inhibitors of eEF-2K.
Results

Time-dependent inhibition and reversibility
We recently reported the expression and purification of recombinant eEF-2K. [11] We determined its kinetic mechanism with the aid of a peptide substrate (acetyl-RKKYKFNED-TERRRFL-amide) [10] and demonstrated that, upon incubation with calcium, calmodulin, and MgATP, it undergoes rapid autophosphorylation on Thr-348, leading to its activation. [12] By a similar approach, a high-throughput screen was performed, and DFTD was identified as an inhibitor of eEF-2K. [13] eEF-2K is a potential target for treating cancer. However, potent specific inhibitors for this enzyme are lacking. Previously, we identified 2,6-diamino-4-(2-fluorophenyl)-4H-thiopyran-3,5-dicarbonitrile (DFTD) as an inhibitor of eEF-2K. Here we describe its mechanism of action against eEF-2K, on the basis of kinetic, mutational, and docking studies, and use chemoinformatic approaches to identify a similar class of carbonitrilecontaining compounds that exhibit the same mechanism of action. We show that DFTD behaves as a reversible covalent inhibitor of eEF-2K with a two-step mechanism of inhibition: a fast initial binding step, followed by a slower reversible inactivation step. Molecular docking suggests that a nitrile group of DFTD binds within 4.5 of the active site Cys146 to form a reversible thioimidate adduct. Because Cys146 is not conserved amongst other related kinases, targeting this residue holds promise for the development of selective covalent inhibitors of eEF-2K.
To assess the mechanism of inhibition of eEF-2K by DFTD, kinetic assays were performed. In these, eEF-2K was incubated with DFTD before the addition of both peptide substrate and MgATP. Under all experimental conditions, the rate of product appearance was found to be linear with time, thus indicating that autophosphorylation is not rate-limiting in the assays. Interestingly, it was noted that the extent of the observed inhibition, as determined by the apparent IC 50 value, increased with the length of incubation (IC 50 = 110 mm and 60 mm with 10 and 30 minute incubations, respectively, at 100 mm ATP).
To examine this time-dependent behavior, eEF-2K (100 nm) was incubated in the presence of different concentrations of DFTD for various lengths of time before initiation of the reaction by dilution of the enzyme inhibitor solution 50-fold into the assay solution containing calmodulin and the substrates. Under these conditions, loosely bound inhibitor would expected to dissociate from the enzyme, and so any loss in observed activity would be presumed to be due to tightly bound inhibitor. The data were assessed according to a two-step model for time-dependent inhibition (Figure 1 A) .
According to this model, I binds rapidly to eEF-2K (step 1) to form E·I, and this is followed by a second, slower step (step 2), which might be reversible, to form E·I*. If we presume that E·I* is incapable of phosphorylating the peptide substrate with an appreciable rate, the concentration of E·I* may be calculated from the observed rate. Figure 1 B shows the calculated concentrations of E·I* after various periods of incubation of eEF-2K with different concentrations of DFTD. To examine whether E·I* formation is reversible, eEF-2K (100 nm) was incubated with DFTD (250 mm) for 1 hour to achieve formation of E·I*. If the formation of E·I* is reversible, the activity should be recovered as depicted in Figure 1 A. Under the conditions of the experiment, the equilibrium strongly favors the dissociation of I from E·I, so the activity of the enzyme may be used to calculate the concentration of E·I* remaining. Figure 1 C shows the losses of E·I* at different times after dilution.
To determine the kinetic parameters, the time-dependence and recovery experiments were fitted globally by use of KinTek Global Explorer (Figure 1 B and C) . DFTD demonstrates a fast initial binding step followed by a slower inactivation step (k 2 = 0.0017 s
À1
). DFTD also demonstrates slow reversibility. Under the conditions of the reaction, the disappearance of E·I* is described by k À2 . The best fit of the data for a first-order reaction gives a value for k À2 of 0.0006 s
, corresponding to a half-life of approximately 19 min. A global fit of the data in Figure 1 B and C furnished a K d (= k À1 /k 1 ) of 140 mm and a slow equilibrium on the enzyme of 2.8 (= k 2 /k À2 , stoichiometric). Thus, at saturation approximately 75 % of the enzyme is covalently bound.
To determine whether DFTD binds to the ATP binding site of eEF-2K, experiments were performed to determine whether incubation with 4 mm ADP (K i % 1 mm) impedes formation of E·I*. Experiments were performed in an identical manner to those described above. eEF-2K (100 nm) was incubated with DFTD (0 or 250 mm) in the presence of ADP (0 or 4 mm) for various lengths of time, and the reactions were then initiated by diluting the enzyme/inhibitor/ADP solution 50-fold into a buffer containing calmodulin and the substrates. As shown in Figure 2 A, the presence of ADP significantly decreased the rate of formation of E·I*, consistently with the notion that ADP competes with DFTD for binding to the active site of eEF-2K. Together, the time-dependent inactivation, reversibility, and the ADP competition assays suggested the likelihood of covalent inhibition at the active site of the enzyme by DFTD.
Docking and mutational studies
To gain further understanding of the mechanism of inhibition of eEF-2K by DFTD, we decided to model it into the active site of eEF-2K. The structure of eEF-2K has not been reported. However, a sequence alignment between eEF-2K and two related alpha kinases-MHCK A and TRPM7, the structures of which are known-reveals 34 and 28 % sequence similarities, respectively, within the catalytic domain (Figure 3 A) . We constructed a homology model of eEF-2K based on these two structures by the methods explained in the Experimental Section. The crystal structure of MHCK A and the homology model of eEF-2K are shown in Figure 3 B, and their alignment is shown in Figure 3 C. The two structures are well aligned, thus indicating good confidence in the accuracy of the predicted homology model. The eEF-2K homology model structure was further confirmed by docking ADP onto the active site; it fitted well into the active site pocket and formed H-bonds similar to those in the ADP·MHCK A complex.
When DFTD was docked into the active site, it was predicted to place a nitrile group in proximity to Cys146 of eEF-2K. Estimates from the modeling place the sulfur atom of Cys146 4.5 from the carbon atom of the nitrile (Figure 4 ). Nitriles have been reported to be inhibitors of cysteine proteases such Figure 1 . A) Schematic model of a two-step inhibition mechanism. B) Timedependent inhibition by DFTD. eEF-2K (100 nm) was incubated with different inhibitor concentrations (*: 500, !: 250,~: 125,^: 62.5, *: 31.25, and *: 0 mm) for different amounts of time (60, 300, 600, 1200, 1800, 3600, and 7200 s). The E + I mix was then diluted 50-fold into the assay reaction. The formation of the E·I* complex versus incubation time was fitted with KinTek Global Explorer for each inhibitor concentration. C) Reversibility of DFTD binding. eEF-2K (100 nm) was incubated with 250 mm inhibitor for 1 h. The E + I mix was diluted 50-fold and incubated for several time periods (0, 300, 600, 1200, 1800, 2700, and 3600 s) before the start of the assay. Loss of the E·I* complex with time after dilution was fitted by the aid of KinTek Global Explorer.
as papain and cysteine cathepsins.
[14] These enzymes each contain a conserved cysteine residue that adds reversibly to the nitriles, [14] thus suggesting the possibility of the nitrile group of DFTD forming a covalent bond to eEF-2K through Cys146. In addition to Cys146, a few other nucleophilic residues that could possibly bind to DFTD (D284, K170, and Y236) were also present in the vicinity of the active site ( Figure 4 ). Therefore, we examined the ability of DFTD to inhibit a number of these mutants of eEF-2K.
Mutation of D284 and K170 resulted in inactive enzymes, and hence the time-dependent activities of these mutants could not be examined. However, the sequence alignment of eEF-2K with TRPM7 and MHCK A (Figure 3 A) shows that both of these residues are conserved and are important for the catalytic activity of eEF-2K.
However, the cysteine and tyrosine mutants retained some activity, thus allowing us to test the potential for inactivation by DFTD. If the inactivation was occurring through nucleophilic attack of the cysteine or tyrosine, then the mutation of these residues would be expected to abrogate the time-dependent inactivation by DFTD.
Because a similar result can also be obtained by the DFTD not binding to the mutated enzyme in the first place, we first tested the binding of DFTD to the cysteine or tyrosine mutants in a dose-response assay at different concentrations of DFTD, after 30 min preincubation of each enzyme with the inhibitor. Under these conditions, DFTD inhibits C146A and C146S with IC 50 values of 890 and 655 mm, respectively (data not shown), thus suggesting that the cysteine might contribute to binding. Tyr236 does not appear to contribute strongly to the binding of DFTD, because the Tyr-to-Phe mutant was inhibited with an IC 50 of 105 mm (data not shown), which is comparable to wildtype eEF-2K. Significantly, inhibition of C146A or C146S by DFTD exhibited no time-dependence, in contrast to wild-type eEF-2K. Thus, when 1 mm of DFTD was incubated with the cysteine mutants for 1 hour and rapidly diluted, maximum activity was attained immediately (Figure 2 B) . In contrast, the tyrosine mutant, as well as the wild-type enzyme, exhibited slow recovery of activity (Figure 2 B) . These data are consistent with a mechanism in which Cys146 reacts with the nitrile group of DFTD to form a reversible thioimidate adduct.
Finally, to further eliminate any possibility of nonspecific interaction between DFTD and the thiols, we tested the ability of DFTD to inactivate eEF-2K in the presence of glutathione. When DFTD (250 mm) was preincubated in the presence of 2.5 mm glutathione for one hour, this had no significant effect on the inactivation or the reversibility rate (data not shown). This supports the notion that the interaction is promoted by the binding of DFTD to the active site and is selective for Cys146 of eEF-2K.
Lastly, to confirm the selectivity of DFTD towards eEF-2K, we also performed kinase assays against TRPM7 (a related kinase) and ERK2 (an unrelated kinase) after incubating each enzyme with DFTD for one hour. DFTD exhibited an IC 50 of 500 mm against TRPM7 and almost no inhibition (IC 50 > 4 mm) against ERK2 (data not shown).
Derivatives identified from virtual screening show a similar mechanism
To further assess the potential for the selective targeting of cysteine by an appended nitrile group, we performed a virtual screen of the NCI diversity set using DFTD as the query compound. The virtual screen protocol is outlined in Figure 5 A. Because both shape and electrostatic complementarity contribute to the biological activities of small ligands, both characteristics were assessed upon screening. Eighty-one compounds identified from the virtual screening were further evaluated in kinase assays. Six compounds, each containing an appended nitrile group, were categorized as inhibitors of eEF-2K (Figure 5 B and Figure S1 in the Supporting Information) exhibiting comparable potency to DFTD, with an apparent IC 50 range of 25-66 mm and similar shape and electrostatic complementarity to DFTD (see Figure 5 C and D for a comparison between DFTD and MDP).
An authentic sample of MDP was purchased and further assessed for time-dependent inhibition by incubation with eEF-2K for varying lengths of time, to reveal time-dependent inacti- vation (Figure 6 A) similar to that of DFTD. Moreover with MDP, activity was recovered with an observed rate constant of 0.00056 s À1 (Figure 6 B) , which is almost identical to that in the case of DFTD. The similarity in the kinetics of inhibition strongly supports the proposed mechanism (i.e., reversible formation of thioimidate adduct), which is summarized in Scheme 1.
Discussion and Conclusions
Covalent inhibitors have attracted significant attention from drug developers in recent years. Covalent kinase inhibitors offer several advantages over firstgeneration reversible ATP-competitive inhibitors. First, they can achieve better potency against millimolar concentrations of ATP inside the cells because the inhibition is time-dependent. Second, with two-step inhibition mechanisms, they offer better selectivity. Third, they are less affected by kinase mutations than reversible ATP competitive inhibitors.
Most of the covalent inhibitors developed against protein kinases target a nonconserved cysteine residue located at the active site of the kinase. Through bioinformatics analysis of the human kinome, Zhang et al. have shown that almost 200 different protein kinases contain a cysteine residue in the vicinity of the nucleotide binding pocket. [15] However, out of all possible cysteine conformations in the kinase active site, only four positions have been targeted so far.
[16] Most of the covalent inhibitors that have been developed against protein kinases such as Rsk, [17] Mek, [18] Nek2, [19] JNK, [16b] BTK, [20] EGFRs, [20] VEGFRs, [21] and FGFRs [22] are irreversible in nature. One of the major drawbacks of irreversible inhibitors is that they might modify off-target proteins and eluci- The distance from the carbon atom of the nitrile group of the compound to the possible nucleophilic residues are as follows: Cys146: 4.5, Lys170: 3.5, Asp284: 4.9, and Tyr236: 3.9 . Yellow represents the G-loop region, whereas green represents the hinge region. Scheme 1. Proposed mechanism of action for DFTD. eEF-2K-S À represents a cysteine residue located in the active site of eEF-2K. date undesired immune response. Reversible covalent inhibitors might represent one of the alternatives to overcome such toxicity-related problems. In a recent study, Serafimova et al. showed that CN-NHiPr, an electron-deficient cyanoacrylamide, tuned to react with cysteine thiols in a rapidly reversible manner and demonstrated similar cellular retention and better potency towards Rsk1 and Rsk2 (relative to the known irreversible inhibitor FMK) in cellular assays, but without the formation of an irreversible adduct. [23] Here, through kinetic, mutational, and docking studies, we have identified members of a class of dicarbonitrile-containing compound as reversible, covalent inhibitors of eEF-2K. Formal elucidation of the mechanism was not possible, because its reversible nature precluded identification of the adduct by standard biophysical approaches such as mass spectrometry. However, the comparable reaction profiles of MDP and DFTD, which each have a similarly appended nitrile group, predicted by docking to be within 4.5 of Cys146, provide strong support for the proposed mechanism, in which the nitrile groups on these compounds each target this nonconserved nucleophilic cysteine residue located at the active site of eEF-2K, forming a reversible thioimidate adduct (Scheme 1). Such nitrile-thiol interactions are also widely observed in cysteine proteases such as papain and cysteine cathepsins, in which the electron-deficient thiol attacks a carbonyl nitrile to form a reversible thioimidate adduct, thus inactivating the enzyme.
[14] Although our initial idea of the possibility of a nitrile-thiol interaction in eEF-2K came from such studies, the two mechanisms differ in a significant aspect. In the case of cysteine proteases, the active site thiol is conserved and is essential for catalysis. However, the active site cysteine in eEF-2K is not conserved amongst other protein kinases. Therefore, the mechanism is new for protein kinases. In addition, targeting the nonconserved cysteine holds promise for the development of selective covalent inhibitors of eEF-2K.
To the best of our knowledge, this is the first evidence of a covalent inhibitor for any atypical class of protein kinases. This is also the first time that nitrile-mediated reversible covalent inhibition has been identified and its mechanism extensively studied for protein kinases. Our studies show that the active site thiol in eEF-2K can be covalently targeted by small molecules. Although we demonstrated it with dicarbonitrile compounds containing nitrile as a warhead group, it opens up possibilities for several other functional groups for identifying either reversible or irreversible covalent inhibitors for eEF-2K.
Experimental Section
Reagents and equipment: The expression and purification of eEF-2K and the synthesis of the peptide substrate (acetyl-RKKYKFNED-TERRRFL-amide) have been reported [11] and were followed accordingly. DFTD was purchased from Chembridge corporation (cata- . A) Time-dependent inhibition by MDP. eEF-2K was incubated with MDP (500 mm) for different amounts of time (0, 60, 300, 600, 1200, 1800, 2700, and 3600 s). The E + I mix was diluted 50-fold into the assay reaction. Formation of the E·I* complex against incubation time was fitted with Equation (1). k obs for the formation of E·I* complex is 0.0031 AE 0.0002 s
À1
. B) Recovery of enzyme activity against MDP. The enzyme was first incubated with MDP (500 mm) for 60 min, then diluted 50-fold and incubated for different time periods, before starting the assay. The decrease in the E·I* complex against incubation time after dilution was fitted by use of Equation (2) . k obs for the loss of the E·I* complex is 0.00056 AE 0.00003 s À1 .
logue no. 5212 007) or made synthetically in our lab. The compound from Chembridge was used in all experiments, and the synthesized compound was used for confirmation. MDP was obtained from Sigma (catalogue no. CCA002401). Structures and purities of DFTD and MDP were verified by NMR ( Figures S2 and S3 ). Resonance forms of compound MDP were also analyzed by NMR. It was found that in DMSO the majority of the compound existed in the 4-(3-methoxyphenyl)-2,6-dioxopiperidine-3,5-dicarbonitrile form (about 86 %), whereas the remainder (about 14 %) existed in the 6-hydroxy-4-(3-methoxyphenyl)-2-oxo-1,2,3,4-tetrahydropyridine-3,5-dicarbonitrile form (see Figure S4 ). Eighty-one chemical compounds identified by virtual screening and used in kinase assays were obtained from the National Cancer Institute (NCI) and used without further characterization. TRPM7 [24] and ERK2 [25] were prepared as previously reported.
Competent cells used for DNA amplification and protein expression were provided by Novagen (Gibbstown, NJ). Yeast extract and tryptone were purchased from US Biological (Swampscott, MA). IPTG and DTT were obtained from USB (Cleveland, OH). All buffer components including HEPES, Trizma base (Tris), sodium chloride, potassium chloride, EDTA, EGTA, calcium chloride, magnesium chloride, Brij-35, Triton X-100, b-mercaptoethanol, benzamidine hydrochloride, TPCK (tosyl phenylalanyl chloromethyl ketone), and PMSF (phenylmethylsulfonyl fluoride) were of highest quality available and were purchased from Sigma. Ni-NTA agarose was supplied by Qiagen (Santa Clarita, CA). Amersham Biosciences (Pittsburgh, PA) provided the FPLC system and the columns for purification. P81 cellulose papers were obtained from Whatman (Piscataway, NJ). ATP was purchased from Roche (Indianapolis, IN), whereas ADP was from MP Biomedicals (Solon, OH). Radiolabeled [g-32 P]-ATP was obtained from PerkinElmer.
Site-directed mutagenesis:
The cloning of human eEF-2K (Genbank accession number NM_013302) in pET32a expression vector has been described. [11] The protein contains a thioredoxin tag followed by a His 6 sequence and a TEV protease cleavage site at the N terminus. Site-directed mutagenesis was performed on eEF-2K to afford different mutants by use of the following primers (mutated residues in bold): C146S: 5'-ga gca atg agg gag agc ttc cgg acg aag-3' (sense) and 5'-ctt cgt ccg gaa gct ctc cct cat tgc tc-3' (antisense), C146A: 5'-a gga gca atg agg gag gcc ttc cgg acg aag aag-3' (sense) and 5'-ctt ctt cgt ccg gaa ggc ctc cct cat tgc tcc t-3' (antisense), Y236F: 5'-c tac atc gag ggc aag ttc atc aag tac aac tcc a-3' (sense) and 5'-t gga gtt gta ctt gat gaa ctt gcc ctc gat gta g-3' (antisense), D284N: 5'-gga gtt ggg gat ctc tac act aac cca cag atc-3' (sense) and 5'-gat ctg tgg gtt agt gta gag atc ccc aac tcc-3' (antisense), K170A: 5'-tcc aac tac gtg gcg gcg cgc tac atc gag cc-3' (sense) and 5'-gg ctc gat gta gcg cgc cgc cac gta gtt gga-3' (antisense).
PCR reactions were performed on a 50 mL scale with 1 PfuUltra HF reaction buffer (Agilent Technologies, Inc., Santa Clara, CA), dNTP mix (200 mm), sense and antisense primers (0.2 mm), DNA template (10 ng), and PfuUltra HF polymerase (Agilent Technologies, Inc., 1 U). The PCR conditions included an initial denaturation step (95 8C for 2 min), followed by 18 PCR cycles (95 8C denaturation step for 30 s, 58 8C primer annealing step for 1 min, and 72 8C extension step for 4 min), followed by a final elongation step at 72 8C for 10 min. The PCR reaction mixture was further incubated at 37 8C for 1 h in the presence of DpnI (10 U) to degrade the methylated parent strand. DpnI-treated sample (1 mL) was transformed into E. coli DH5a chemical competent cells. A single colony was isolated and amplified, and the extracted plasmid DNA was verified for sequencing at the ICMB core facilities, UT-Austin, with an applied Biosystems automated DNA sequencer.
Kinase assays: All experiments were performed in DMSO (5 %) to improve compound solubility because DMSO (5 %) did not alter enzyme activity ( Figure S5 ). All assays were performed at 30 8C in assay buffer [HEPES (pH 7.5, 25 mm), KCl (50 mm), EDTA (0.1 mm), EGTA (0.1 mm), DTT (2 mm), MgCl 2 (10 mm), BSA (40 mg mL À1 ), DMSO (5 %)]. For IC 50 measurement with DFTD against protein variations, WT or mutant eEF-2K (2 nm for WT, C146A, and Y236F, 10 nm for C146S) were preincubated with various concentrations of DFTD (0-1000 mm) in assay buffer containing CaCl 2 (150 mm), calmodulin (1 mm), triton X-100 (0.01 %), and peptide substrate (50 mm) for 30 min. Similarly, for IC 50 measurement with MDP and five additional derivatives, WT eEF-2K (2 nm) was preincubated with various concentrations of inhibitors (0-1000 mm) in assay buffer containing CaCl 2 (150 mm), calmodulin (1 mm), triton X-100 (0.01 %), and peptide substrate (50 mm) for 60 min. After the indicated time, the reactions were started by addition of [g-32 P]-ATP (100 mm, specific activity = 1000 cpm pmol À1 ). The product formation was monitored over 2.5 min by spotting aliquots (10 mL) onto P81 cellulose papers at fixed time point intervals. The papers were washed with phosphoric acid (50 mm, five times for 10 min each) and then dried after acetone washing. The amounts of radiolabeled phosphopeptides were determined by counting the associated counts per min on a scintillation counter (Packard 1500) at a s value of 2.
Time-dependent inhibition experiments: Time-dependent inhibition by DFTD and by MDP was tested by means of dilution experiments. eEF-2K at a concentration of 100 nm (50 times higher than the assay concentration) was incubated with different concentrations of inhibitor (0-500 mm) for different amounts of time in a buffer containing HEPES (pH 7.5, 25 mm), BSA (40 mg mL À1 ), DTT (2 mm), and DMSO (5 %). For ADP protection experiments, a similar incubation was performed with DFTD (0 or 250 mm) in the presence or absence of ADP (4 mm). The incubation mixtures were then diluted 50-fold into the assay buffer containing CaCl 2 (150 mm), CaM (1 mm), and peptide substrate (50 mm). Immediately after the dilution, the assays were started with the addition of [g-32 P]-ATP (100 mm, specific activity = 1000 cpm pmol
À1
). The product formation was monitored over 2.5 min by spotting aliquots (10 mL) onto P81 cellulose papers at fixed time intervals. The papers were washed with phosphoric acid (50 mm, five times for 10 min each) and then dried after acetone washing. The amounts of radiolabeled phospho-peptides were determined by counting the associated counts per min on a scintillation counter (Packard 1500) at a s value of 2.
Recovery experiments: To test the wild-type enzyme recovery after inactivation by DFTD and by MDP, enzyme at a concentration 50 times higher than the assay concentration was incubated for 1 h in the presence of each inhibitor (0 or 250 mm for DFTD, 0 or 500 mm for MDP) in buffer containing HEPES (pH 7.5, 25 mm), BSA (40 mg mL À1 ), DTT (2 mm), and DMSO (5 %). Similarly, to test the recovery of cysteine mutants against DFTD, mutant enzymes C146A, C146S, and Y236F were incubated for 1 h in the presence of DFTD (0 or 1000 mm). After 1 hour, the enzyme and inhibitor mixtures were diluted 50-fold into the assay buffer containing peptide substrate (50 mm). The diluted enzyme and inhibitor mixtures were incubated for various times, after which the assays were then started with the addition of CaCl 2 (150 mm), calmodulin (1 mm), and [g-32 P]-ATP (100 mm, specific activity = 1000 cpm pmol À1 ). The product formation was monitored over 2.5 min by spotting aliquots (10 mL) onto P81 cellulose papers at fixed time point intervals. The phosphorylated counts per min were determined in similar manner to that described above.
Homology modeling: The amino acid sequence of human eEF-2 kinase (accession number: 21618568), was retrieved from SWIS-SPROT. [26] Sequences and structures of the alpha-kinase domains of MHCK A and TRPM7 were obtained from the RSCB protein data bank at 1.6 and 2.0 resolutions (PDB ID: 3LKM [27] and 1IA9 [28] ). The multiple sequence alignment was performed by using the CLUSTAL W2 server (http://www.ebi.ac.uk/Tools/msa/clustalw2/). This alignment was then manually adjusted to minimize the number of gaps and insertions. Our final alignment is similar to that published by other groups. [27] [28] The final sequence and structural alignments of human eEF-2K to MHCK A and TRPM7 shows about 34 and 28 % sequence identity of the kinase domain, thus suggesting that the most important part of the sequence is conserved. Therefore, we conclude that this alignment is suitable for the construction of a reliable 3D model for human eEF-2K. The 3D model of the human eEF-2K, based on the sequence alignment and the X-ray crystal structures of MHCK A and TRPM7, was built by application of homology modeling methods implemented in the program MODELER 9V5. [29] MODELER's variable target function method (VTFM) and MD simulated annealing [30] were used to refine 20 initially randomized models. The final models were evaluated with PROCHECK [31] and Prosa 2003. [32] The structure and sequence were visualized with the programs VMD [33] and Jalview. [34] Shape and electrostatic virtual screening: The compound DFTD served as the query ligand. ChemDraw 3D ultra (8.0, CambridgeSoft) was used to draw and minimize a three-dimensional conformer of DFTD. Virtual screening was performed with software from OpenEye (OpenEye Scientific Software) and the chemical database NCI diversity set (http://cactus.nci.nih.gov/download/nci/). Omega [35] was used to generate up to 20 conformers of each NCI molecule. ROCS [36] was utilized for three-dimensional shape comparisons, and the 500 molecules were ranked on the basis of the combo score function, a sum of scaled color score and shape Tanimoto score. The shape Tanimoto score is given by the following: Shape Tanimoto = V C /(V A +V B ÀV C ), where V C is the volume in common between the two molecules, V A is the total volume of the query molecule, and V B is the total volume of the target molecule. The coefficient ranges from 0 (no shape overlap) to 1 (identical shape).
The top 1000 molecules from ROCS [36] were then reranked in EON, [37] and the top 500 were passed to the next step for rescoring. In EON, [37] the Poisson-Boltzmann equation is solved to calculate the electrostatic potential on the nodes of a 3D grid constructed around a molecule. The molecule has MMFF94 nuclei-centered charges assigned. The OpenEye Electrostatic Tanimoto similarity is given by: Electrostatic Tanimoto = AB/(AA+BBÀAB), where A is the electrostatic potential around the query molecule and B is the electrostatic potential around the target molecule. The coefficient ranges from À 1 = 3 , when two molecules have equal but opposite potentials, to 1, when the two molecules have identical potentials.
In the final rescoring stage, composite scores, which weight 50 % of the shape-based and 50 % of the electrostatic-based similarities, were used to rerank the 500 + 500 molecules from previous steps, resulting in the top 125 molecules. Of these, 81 compounds were available and tested in kinase assays. Docking: Docking of the compound to the kinase homology model was performed with Gold5.1 [38] and the ChemPLP fitness function. [39] Twenty independent docking attempts were conducted for the compound with the aid of the generic algorithm implemented in Gold5.1. The results of each docking were ranked according to the ChemPLP fitness score and virtually inspected. It turned out that 17 out of 20 of the docked poses agree with the orientation shown in Figure 4 . The remaining three poses, which had the lowest scores of the 20 poses, suggest an orientation in which the fluorine atom is pointing is the opposite direction while the position of the dicarbonitrile-containing ring remains the same.
Data analysis: The two-step inhibition mechanism for DFTD was fitted globally with the aid of KinTek global explorer (KinTek Corporation, Austin, TX). The formation or loss of product over time were fitted by use of Equations (1) and (2), respectively. The inhibitor dose-response data were fitted by use of Equation (3).
Àk obs t Þ ð1Þ
PðtÞ ¼ P max ðe Àkobst Þ ð2Þ
The parameters used above are as follows: P(t) is the amount of product at time t, P max is maximum product formation, P 0 is the amount of product at t = 0, v i is the observed velocity in the presence of inhibitor, v 0 is the observed velocity in the absence of inhibitor, I is the concentration of inhibitor, IC 50 is the inhibitor concentration required to achieve 50 % inhibition, and h is the Hill coefficient. Each data point represents the mean AE standard deviation from three replicates.
